Skip to main content
. 2021 Oct 4;12:727117. doi: 10.3389/fpsyt.2021.727117

Figure 4.

Figure 4

Percentage of patients excluded from recent large MDD trials of the hallucinogenic drug psilocybin and the non-hallucinogenic drug vortioxetine. A comprehensive analysis of all psychedelic trials is beyond the scope of this review. For additional information on the broad range of smaller trials with psychedelics, please see (262, 263).